Markers predicting clinical benefit in breast cancer from microtubule-targeting agents
Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Annals Of Oncology 2007, 18: xii15-xii20. PMID: 18083698, DOI: 10.1093/annonc/mdm534.Peer-Reviewed Original ResearchConceptsMicrotubule-targeting agentsSubset of patientsEstrogen receptor negativityBreast cancer patientsNon-cross resistanceMicrotubule-associated protein tauMechanism of actionReceptor negativityClinical benefitPatient groupCancer patientsClinical trialsPoor responseHER2 amplificationClinical dataClinical studiesBreast cancerTaxane resistanceBetaIII-tubulinProtein tauP-glycoproteinPharmacogenomic analysisTaxanesLow expressionPatients